Using the same conditions on 99 tumor sections of mixed types, we verified that most triple-negative tumors (34 out of 40, 85%) expressed HORMAD1 and/or CT83 (Fig. S3E), and this activation is specific to the triple-negative subtype (p-value < 10−4). Here, CT83 is linked to neoplasm.